China Post-marketing Surveillance (PMS) Study of Fabrazyme®
Status:
Recruiting
Trial end date:
2023-10-11
Target enrollment:
Participant gender:
Summary
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the
efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese
participants with Fabry Disease.